Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic
Authors:
J. Starý 1; V. Vávra 1; J. Zuna 1; P. Sedláček 1; V. Mihál 2; J. Štěrba 3; K. Toušovská 4; D. Pospíšilová 2; D. Mendelová 3; J. Hak 4; P. Smíšek 1; O. Hrušák 1; E. Mejstříková 1; Z. Zemanová 5; K. Michalová 5; M. Jarošová 6; A. Oltová 7; P. Gajdoš 1; R. Formánková 1; P. Keslová 1; Y. Jabali 8; B. Blažek 9; Z. Černá 10; D. Procházková 11; K. Kramarzová 1; A. Vrzalová 1; J. Housková 12; J. Trka 1
Authors‘ workplace:
Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Praha, 2Dětská klinika LF UP a FN Olomouc, 3Klinika dětské onkologie FN Brno, 4Dětská klinika FN Hradec Králové, 5Centrum nádorové cytogenetiky, Ústav klinické biochemie a laboratorní diagnostiky
1
Published in:
Transfuze Hematol. dnes,15, 2009, No. 2, p. 83-90.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Acute lymphoblastic leukemia (ALL) affecting infants is a rare malignancy with the biological behavior different from the leukemia of older children. About 80% infants have a rearrangement of the MLL gene at the chromosomal locus 11q23. The most frequent abnormality is the t(4;11)(q21;q23) translocation producing the MLL-AF4 fusion gene. The MLL+ ALL originates usually in the immature B-cell precursors with aberrant expression of myeloid antigens. It is characterized by hyperleukocytosis, poor initial treatment response and high risk of the early relapse. Treatment results are significantly worse than in older children. Current protocols usually combine elements used in the therapy of both lymphoid and myeloid acute leukemias. Between 1990 and 1999, twenty-one infants were diagnosed with ALL in the Czech Republic and only 6 of them were treated according to a protocol designed specifically for the infants. Five-years event-free survival (EFS) was 33 %, only one out of the ten children with MLL-AF4 fusion gene was cured. Between 2000 and 2005, fourteen infants were diagnosed with ALL and 13 of them were treated in the international randomized study Interfant 99. Ten children bear an MLL rearrangement, most frequently the t(4;11) in 6 of them. Flow cytometry showed pro-B ALL immunophenotype in nine patients, pre-B ALL in two cases and two children were diagnosed as T-ALL (unusual in the infant age) with complex karyotype. Ten children had WBC ≥ 50 000/μl, 7 infants were younger than 6 months at diagnosis. Twelve children achieved complete remission. Two children with a poor early treatment response were stratified into the high risk group, all others into the standard risk group. Seven children suffered from relapse and one child developed secondary malignancy. Altogether, 7 children are alive, four of them in the first remission. Five children underwent 7 stem cell transplantations from the unrelated (n = 6) or HLA identical donor (n = 1) (only one of them in the first remission). Five-years EFS of 482 patients enrolled in the international study Interfant 99 is 46% and overall survival 55% showing the improvement in comparison with majority of the previous studies.
Key words:
acute lymphoblastic leukemia, infants, Interfant 99 study, MLL rearrangement, t(4;11) translocation
Sources
1. Jansen MWJC, Corral L, van der Velden VHJ, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21: 633–641.
2. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909–1915.
3. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700–706.
4. Mann G, Cazzaniga G, van der Velden VHJ, et al. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The „big sister“ of the infant disease? Leukemia 2007; 21: 642–646.
5. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profilig. Cancer Cell 2002; 1: 133–143.
6. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993; 363: 358–360.
7. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA. 1997; 94: 13950–13954.
8. Ford AM, Bennett CA, Price CM, et al. Fetal origins of the TEL-AM1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA. 1998; 95: 4584–4588.
9. Wiemels JL, Ford AM, van Wering ER, et al. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057–1062.
10. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499–1503.
11. Trka J, Zuna J, Hrušák O, et al. No evidence for MLL/AF4 expression in normal cord blood samples. Blood 1999; 93: 1106–1110.
12. Eguchi M, Eguchi-Ishimae M, Knight D, et al. MLL chimeric protein activation renders cells vulnerable to chromosomal damage: an explanation for the very short latency of infant leukemia. Genes Chromosomes Cancer 2006; 45: 754–760.
13. Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001; 61: 2542–2546.
14. Ross JA. Dietary flavonoids and the MLL gene: a pathway to infant leukemia? PNAS 2000; 97: 4411–4413.
15. Silvermann LB, McLean TW, Gerber RD, et al. Intensified therapy for infants with acute lymphoblastic leukema. Cancer 1997; 80: 2285–2295.
16. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209– 1217.
17. Jabali Y, Starý J, Hak J, et al. Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic. Med Pediatr Oncol 2000; 34: 493–495.
18. Starý J, Gajdoš P, Trka J, et al. Akutní lymfoblastická leukemie u kojenců. Transfuze Hematol dnes 2002; 8: 47–54.
19. European group for the immunological characterisation of leukaemias (EGIL), Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukaemias. Leukemia 1995; 9: 1783–1786.
20. van der Burg M, Beverloo HB, Langera AW, et al. Rapid and sensitive detection of all types of MLL gene translocations with single FISH probe set. Leukemia 1999; 13: 2107–2113.
21. Andersson A, Höglund M, Johansson B, et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia 2001; 15: 1293–1300.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.
24. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia – implications for treatment of infants. Leukemia 1998; 12: 1344–1348.
25. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomized trial. Lancet 2007; 370: 240–250.
26. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Childrenęs Oncology Group. Blood 2006; 108: 441–451.
27. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527–3534.
28. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007; 21: 2258–2263.
29. Nagayama J, Tomizawa D, Koh K, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006; 107: 4663–4665.
30. Lonnerholm G, Valsecchi MG, de Lorenzo P, et al. Pharmacokinetics of high dose methotrexate in infants treated for acute lymphoblastic leukemia. Ped Blood Cancer 2009; 52: 596–601.
31. Hempel G, Relling MV, de Rossi G, et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the Interfant 99 protocol. Ped Blood Cancer, submitted.
32. Stam RW, Schneider P, de Lorenzo P, et al. Prognostic significance of high-level Flt3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2007; 110: 2774–2775.
33. Stam RW, den Boer ML, Pieters R. Towards targeted therapy for infant acute lymphoblastic leukemia. Br J Haematol 2006; 132: 539–551.
34. Rubnitz JE, Raimondi SC, Xin Tong, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002; 20: 2302–2309.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 2
Most read in this issue
- Microchimerism – on the edge of incipient AML relapse?
- Clonal evolution in chronic lymphocytic leukemia
- Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic
- Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome